17 recherche sur le mot-clé 'Methylphenidate'

Effects of methylphenidate on executive functioning in children and adolescents with ADHD after long-term use: a randomized, placebo-controlled discontinuation study / Paul T. ROSENAU in Journal of Child Psychology and Psychiatry, 62-12 (December 2021)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 62-12 (December 2021) . - p.1444-1452 Titre : Effects of methylphenidate on executive functioning in children and adolescents with ADHD after long-term use: a randomized, placebo-controlled discontinuation study Type de document : texte imprimé Auteurs : Paul T. ROSENAU, Auteur ; Thaïra J.C. OPENNEER, Auteur ; Anne-Flore M. MATTHIJSSEN, Auteur ; Gigi H.H. VAN DE LOO-NEUS, Auteur ; Jan K. BUITELAAR, Auteur ; Barbara J. VAN DEN HOOFDAKKER, Auteur ; Pieter J. HOEKSTRA, Auteur ; Andrea DIETRICH, Auteur Article en page(s) : p.1444-1452 Langues : Anglais (eng) Mots-clés : Adolescent  Attention Deficit Disorder with Hyperactivity/drug therapy  Central Nervous System Stimulants/adverse effects  Child  Double-Blind Method  Executive Function  Humans  Methylphenidate/adverse effects  Netherlands  Treatment Outcome  attention-deficit/hyperactivity disorder  executive functioning  long-term  methylphenidate  working memory Index. décimale : PER Périodiques Résumé : BACKGROUND: Methylphenidate may improve executive functioning in children with attention-deficit/hyperactivity disorder (ADHD). However, it is unclear if there are still acute effects of methylphenidate on executive functioning after long-term use. METHODS: In a randomized double-blind, placebo-controlled discontinuation study, 94 children and adolescents (ages 8-18 years) who used methylphenidate beyond two years were either assigned to seven weeks of continued treatment with 36 or 54 mg of extended-release methylphenidate or to gradual withdrawal over three weeks to placebo for four weeks. Performance on neuropsychological tasks, measuring working memory, response inhibition, attentional flexibility and psychomotor speed was compared between both groups using mixed models for repeated measures. Additionally, we investigated within the discontinuation group if a deterioration on the investigator-rated Clinical Global Impressions Improvement scale after withdrawing to placebo was related to a worse performance on the neuropsychological tasks. This study was registered in the Netherlands Trial Register (www. Trialregister.nl) with identifier 5252. RESULTS: After withdrawal of methylphenidate, the discontinuation group made more errors on working memory (β = -1.62, SD = 0.56, t = -2.88, p = .01, Cohen's f2 = .14), independent from reaction time compared to baseline, in contrast to the continuation group. We did not find differences in changes in response inhibition, attentional flexibility and psychomotor speed between the two groups. Also, there were no significant differences in task measures between the participants who deteriorated clinically and those who did not. CONCLUSIONS: Our study shows that methylphenidate has a beneficial effect on working memory after two years of use. Future studies should explore whether cognitive outcomes may aid clinical decision-making on the continued use of methylphenidate, given dissociation between cognitive and behavioural effects of stimulant medication. En ligne : http://dx.doi.org/10.1111/jcpp.13419 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=456 [article] Effects of methylphenidate on executive functioning in children and adolescents with ADHD after long-term use: a randomized, placebo-controlled discontinuation study [texte imprimé] / Paul T. ROSENAU, Auteur ; Thaïra J.C. OPENNEER, Auteur ; Anne-Flore M. MATTHIJSSEN, Auteur ; Gigi H.H. VAN DE LOO-NEUS, Auteur ; Jan K. BUITELAAR, Auteur ; Barbara J. VAN DEN HOOFDAKKER, Auteur ; Pieter J. HOEKSTRA, Auteur ; Andrea DIETRICH, Auteur . - p.1444-1452. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 62-12 (December 2021) . - p.1444-1452 Mots-clés : Adolescent  Attention Deficit Disorder with Hyperactivity/drug therapy  Central Nervous System Stimulants/adverse effects  Child  Double-Blind Method  Executive Function  Humans  Methylphenidate/adverse effects  Netherlands  Treatment Outcome  attention-deficit/hyperactivity disorder  executive functioning  long-term  methylphenidate  working memory Index. décimale : PER Périodiques Résumé : BACKGROUND: Methylphenidate may improve executive functioning in children with attention-deficit/hyperactivity disorder (ADHD). However, it is unclear if there are still acute effects of methylphenidate on executive functioning after long-term use. METHODS: In a randomized double-blind, placebo-controlled discontinuation study, 94 children and adolescents (ages 8-18 years) who used methylphenidate beyond two years were either assigned to seven weeks of continued treatment with 36 or 54 mg of extended-release methylphenidate or to gradual withdrawal over three weeks to placebo for four weeks. Performance on neuropsychological tasks, measuring working memory, response inhibition, attentional flexibility and psychomotor speed was compared between both groups using mixed models for repeated measures. Additionally, we investigated within the discontinuation group if a deterioration on the investigator-rated Clinical Global Impressions Improvement scale after withdrawing to placebo was related to a worse performance on the neuropsychological tasks. This study was registered in the Netherlands Trial Register (www. Trialregister.nl) with identifier 5252. RESULTS: After withdrawal of methylphenidate, the discontinuation group made more errors on working memory (β = -1.62, SD = 0.56, t = -2.88, p = .01, Cohen's f2 = .14), independent from reaction time compared to baseline, in contrast to the continuation group. We did not find differences in changes in response inhibition, attentional flexibility and psychomotor speed between the two groups. Also, there were no significant differences in task measures between the participants who deteriorated clinically and those who did not. CONCLUSIONS: Our study shows that methylphenidate has a beneficial effect on working memory after two years of use. Future studies should explore whether cognitive outcomes may aid clinical decision-making on the continued use of methylphenidate, given dissociation between cognitive and behavioural effects of stimulant medication. En ligne : http://dx.doi.org/10.1111/jcpp.13419 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=456

Comorbidité entre troubles Dys et TDAH mécanismes partagés et réponses au traitement par méthylphénidate / Hugo PEYRE in Approche Neuropsychologique des Apprentissages chez l'Enfant - A.N.A.E., 197 (Octobre 2025)

Public ISBD [article]  inApproche Neuropsychologique des Apprentissages chez l'Enfant - A.N.A.E. > 197 (Octobre 2025) . - p.479-483 Titre : Comorbidité entre troubles Dys et TDAH mécanismes partagés et réponses au traitement par méthylphénidate Type de document : texte imprimé Auteurs : Hugo PEYRE, Auteur Année de publication : 2025 Article en page(s) : p.479-483 Langues : Français (fre) Mots-clés : Comorbidité  TDAH  Troubles Dys  Méthylphénidate Index. décimale : PER Périodiques Résumé : Les troubles Dys sont fréquemment comorbides avec le trouble déficit de l'attention avec ou sans hyperactivité (TDAH), une association qui interroge à la fois les mécanismes de la comorbidité et les implications thérapeutiques. Ce travail poursuit ces deux objectifs : 1) explorer les mécanismes sous-jacents à la comorbidité entre TDAH et troubles Dys, en mobilisant des données épidémiologiques et génétiques. Les données disponibles suggèrent l'existence de facteurs de risque partagés, mais aussi d'influences développementales entre les deux types de troubles, et 2) évaluer l'efficacité et la tolérance du méthylphénidate dans cette population comorbide. Sur le plan thérapeutique, les études actuelles montrent que le méthylphénidate est globalement bien toléré et efficace chez les enfants présentant à la fois un TDAH et un trouble Dys, bien que les recherches spécifiques sur cette population soient encore limitées. Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=583 [article] Comorbidité entre troubles Dys et TDAH mécanismes partagés et réponses au traitement par méthylphénidate [texte imprimé] / Hugo PEYRE, Auteur . - 2025 . - p.479-483. Langues : Français (fre) in Approche Neuropsychologique des Apprentissages chez l'Enfant - A.N.A.E. > 197 (Octobre 2025) . - p.479-483 Mots-clés : Comorbidité  TDAH  Troubles Dys  Méthylphénidate Index. décimale : PER Périodiques Résumé : Les troubles Dys sont fréquemment comorbides avec le trouble déficit de l'attention avec ou sans hyperactivité (TDAH), une association qui interroge à la fois les mécanismes de la comorbidité et les implications thérapeutiques. Ce travail poursuit ces deux objectifs : 1) explorer les mécanismes sous-jacents à la comorbidité entre TDAH et troubles Dys, en mobilisant des données épidémiologiques et génétiques. Les données disponibles suggèrent l'existence de facteurs de risque partagés, mais aussi d'influences développementales entre les deux types de troubles, et 2) évaluer l'efficacité et la tolérance du méthylphénidate dans cette population comorbide. Sur le plan thérapeutique, les études actuelles montrent que le méthylphénidate est globalement bien toléré et efficace chez les enfants présentant à la fois un TDAH et un trouble Dys, bien que les recherches spécifiques sur cette population soient encore limitées. Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=583

Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder / Anne-Claude V. BÉDARD in Journal of Child Psychology and Psychiatry, 56-1 (January 2015)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 56-1 (January 2015) . - p.40-48 Titre : Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder Type de document : texte imprimé Auteurs : Anne-Claude V. BÉDARD, Auteur ; Mark A. STEIN, Auteur ; Jeffrey M. HALPERIN, Auteur ; Beth KRONE, Auteur ; Estrella RAJWAN, Auteur ; Jeffrey H. NEWCORN, Auteur Article en page(s) : p.40-48 Langues : Anglais (eng) Mots-clés : Attention-deficit/hyperactivity disorder  atomoxetine  methylphenidate  attention  vigilance Index. décimale : PER Périodiques Résumé : Background This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with attention-deficit/hyperactivity disorder (ADHD). It was hypothesized that performance would be improved by both treatments, but response profiles would differ because the medications work via different mechanisms. Methods One hundred and two youth (77 male; mean age = 10.5 ± 2.7 years) with ADHD received ATX (1.4 ± 0.5 mg/kg) and MPH (52.4 ± 16.6 mg) in a randomized, double-blind, crossover design. Medication was titrated in 4–6-week blocks separated by a 2-week placebo washout. Inhibitory control and attention measures were obtained at baseline, following washout, and at the end of each treatment using Conners' Continuous Performance Test II (CPT-II), which provided age-adjusted T-scores for reaction time (RT), reaction time variability (RT variability), and errors. Repeated-measures analyses of variance were performed, with Time (premedication, postmedication) and Treatment type (ATX, MPH) entered as within-subject factors. Data from the two treatment blocks were checked for order effects and combined if order effects were not present. Clinical trial registration: Clinicaltrials.gov: NCT00183391. Results Main effects for Time on RT (p = .03), RTSD (p = .001), and omission errors (p = .01) were significant. A significant Drug × Time interaction indicated that MPH improved RT, RTSD, and omission errors more than ATX (p < .05). Changes in performance with treatment did not correlate with changes in ADHD symptoms. Conclusions MPH has greater effects than ATX on CPT measures of sustained attention in youth with ADHD. However, the dissociation of cognitive and behavioral change with treatment indicates that CPT measures cannot be considered proxies for symptomatic improvement. Further research on the dissociation of cognitive and behavioral endpoints for ADHD is indicated. En ligne : http://dx.doi.org/10.1111/jcpp.12272 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=259 [article] Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder [texte imprimé] / Anne-Claude V. BÉDARD, Auteur ; Mark A. STEIN, Auteur ; Jeffrey M. HALPERIN, Auteur ; Beth KRONE, Auteur ; Estrella RAJWAN, Auteur ; Jeffrey H. NEWCORN, Auteur . - p.40-48. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 56-1 (January 2015) . - p.40-48 Mots-clés : Attention-deficit/hyperactivity disorder  atomoxetine  methylphenidate  attention  vigilance Index. décimale : PER Périodiques Résumé : Background This study examined the effects of atomoxetine (ATX) and OROS methylphenidate (MPH) on laboratory measures of inhibitory control and attention in youth with attention-deficit/hyperactivity disorder (ADHD). It was hypothesized that performance would be improved by both treatments, but response profiles would differ because the medications work via different mechanisms. Methods One hundred and two youth (77 male; mean age = 10.5 ± 2.7 years) with ADHD received ATX (1.4 ± 0.5 mg/kg) and MPH (52.4 ± 16.6 mg) in a randomized, double-blind, crossover design. Medication was titrated in 4–6-week blocks separated by a 2-week placebo washout. Inhibitory control and attention measures were obtained at baseline, following washout, and at the end of each treatment using Conners' Continuous Performance Test II (CPT-II), which provided age-adjusted T-scores for reaction time (RT), reaction time variability (RT variability), and errors. Repeated-measures analyses of variance were performed, with Time (premedication, postmedication) and Treatment type (ATX, MPH) entered as within-subject factors. Data from the two treatment blocks were checked for order effects and combined if order effects were not present. Clinical trial registration: Clinicaltrials.gov: NCT00183391. Results Main effects for Time on RT (p = .03), RTSD (p = .001), and omission errors (p = .01) were significant. A significant Drug × Time interaction indicated that MPH improved RT, RTSD, and omission errors more than ATX (p < .05). Changes in performance with treatment did not correlate with changes in ADHD symptoms. Conclusions MPH has greater effects than ATX on CPT measures of sustained attention in youth with ADHD. However, the dissociation of cognitive and behavioral change with treatment indicates that CPT measures cannot be considered proxies for symptomatic improvement. Further research on the dissociation of cognitive and behavioral endpoints for ADHD is indicated. En ligne : http://dx.doi.org/10.1111/jcpp.12272 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=259

Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study / Soo-Jeong KIM in Journal of Autism and Developmental Disorders, 47-8 (August 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-8 (August 2017) . - p.2307-2313 Titre : Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study Type de document : texte imprimé Auteurs : Soo-Jeong KIM, Auteur ; Sophia SHONKA, Auteur ; William P. FRENCH, Auteur ; Jennifer STRICKLAND, Auteur ; Lindsey MILLER, Auteur ; Mark A. STEIN, Auteur Article en page(s) : p.2307-2313 Langues : Anglais (eng) Mots-clés : Attention deficit hyperactivity disorder  ADHD  Autism spectrum disorder  ASD  Methylphenidate Index. décimale : PER Périodiques Résumé : Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy. En ligne : https://doi.org/10.1007/s10803-017-3125-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 [article] Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study [texte imprimé] / Soo-Jeong KIM, Auteur ; Sophia SHONKA, Auteur ; William P. FRENCH, Auteur ; Jennifer STRICKLAND, Auteur ; Lindsey MILLER, Auteur ; Mark A. STEIN, Auteur . - p.2307-2313. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-8 (August 2017) . - p.2307-2313 Mots-clés : Attention deficit hyperactivity disorder  ADHD  Autism spectrum disorder  ASD  Methylphenidate Index. décimale : PER Périodiques Résumé : Attention deficit/hyperactivity disorder (ADHD) symptoms are common in youth with autism spectrum disorders (ASD) and are frequently treated with stimulant medications. Twenty-seven children were randomized to different dose titration schedules, and ADHD symptoms, tolerability, and aberrant behaviors were assessed weekly during a 6-week trial with long-acting liquid methylphenidate (MPH). MPH at low to moderate doses was effective in reducing ADHD symptoms and was well tolerated in young children with ASD and ADHD. Future studies are needed to assess generalization and maintenance of efficacy. En ligne : https://doi.org/10.1007/s10803-017-3125-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314

Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism / Yuta HARA in Autism Research, 9-9 (September 2016)  

Public ISBD [article]  inAutism Research > 9-9 (September 2016) . - p.926-939 Titre : Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism Type de document : texte imprimé Auteurs : Yuta HARA, Auteur ; Yukio AGO, Auteur ; Atsuki TARUTA, Auteur ; Keisuke KATASHIBA, Auteur ; Shigeru HASEBE, Auteur ; Erika TAKANO, Auteur ; Yusuke ONAKA, Auteur ; Hitoshi HASHIMOTO, Auteur ; Toshio MATSUDA, Auteur ; Kazuhiro TAKUMA, Auteur Article en page(s) : p.926-939 Langues : Anglais (eng) Mots-clés : valproic acid  methylphenidate  atomoxetine  behavioral analysis  animal model Index. décimale : PER Périodiques Résumé : Rodents exposed prenatally to valproic acid (VPA) show autism-related behavioral abnormalities. We recently found that prenatal VPA exposure causes a reduction of dopaminergic activity in the prefrontal cortex of male, but not female, mice. This suggests that reduced prefrontal dopaminergic activity is associated with behavioral abnormalities in VPA-treated mice. In the present study, we examined whether the attention deficit/hyperactivity disorder drugs methylphenidate and atomoxetine (which increase dopamine release in the prefrontal cortex, but not striatum, in mice) could alleviate the behavioral abnormalities and changes in dendritic spine morphology induced by prenatal VPA exposure. We found that methylphenidate and atomoxetine increased prefrontal dopamine and noradrenaline release in VPA-treated mice. Acute treatment with methylphenidate or atomoxetine did not alleviate the social interaction deficits or recognition memory impairment in VPA-treated mice, while chronic treatment for 2 weeks did. Methylphenidate or atomoxetine for 2 weeks also improved the prenatal VPA-induced decrease in dendritic spine density in the prefrontal cortex. The effects of these drugs on behaviors and dendritic spine morphology were antagonized by concomitant treatment with the dopamine-D1 receptor antagonist SCH39166 or the dopamine-D2 receptor antagonist raclopride, but not by the α2-adrenoceptor antagonist idazoxan. These findings suggest that chronic treatment with methylphenidate or atomoxetine improves abnormal behaviors and diminishes the reduction in spine density in VPA-treated mice via a prefrontal dopaminergic system-dependent mechanism. En ligne : http://dx.doi.org/10.1002/aur.1596 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=294 [article] Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism [texte imprimé] / Yuta HARA, Auteur ; Yukio AGO, Auteur ; Atsuki TARUTA, Auteur ; Keisuke KATASHIBA, Auteur ; Shigeru HASEBE, Auteur ; Erika TAKANO, Auteur ; Yusuke ONAKA, Auteur ; Hitoshi HASHIMOTO, Auteur ; Toshio MATSUDA, Auteur ; Kazuhiro TAKUMA, Auteur . - p.926-939. Langues : Anglais (eng) in Autism Research > 9-9 (September 2016) . - p.926-939 Mots-clés : valproic acid  methylphenidate  atomoxetine  behavioral analysis  animal model Index. décimale : PER Périodiques Résumé : Rodents exposed prenatally to valproic acid (VPA) show autism-related behavioral abnormalities. We recently found that prenatal VPA exposure causes a reduction of dopaminergic activity in the prefrontal cortex of male, but not female, mice. This suggests that reduced prefrontal dopaminergic activity is associated with behavioral abnormalities in VPA-treated mice. In the present study, we examined whether the attention deficit/hyperactivity disorder drugs methylphenidate and atomoxetine (which increase dopamine release in the prefrontal cortex, but not striatum, in mice) could alleviate the behavioral abnormalities and changes in dendritic spine morphology induced by prenatal VPA exposure. We found that methylphenidate and atomoxetine increased prefrontal dopamine and noradrenaline release in VPA-treated mice. Acute treatment with methylphenidate or atomoxetine did not alleviate the social interaction deficits or recognition memory impairment in VPA-treated mice, while chronic treatment for 2 weeks did. Methylphenidate or atomoxetine for 2 weeks also improved the prenatal VPA-induced decrease in dendritic spine density in the prefrontal cortex. The effects of these drugs on behaviors and dendritic spine morphology were antagonized by concomitant treatment with the dopamine-D1 receptor antagonist SCH39166 or the dopamine-D2 receptor antagonist raclopride, but not by the α2-adrenoceptor antagonist idazoxan. These findings suggest that chronic treatment with methylphenidate or atomoxetine improves abnormal behaviors and diminishes the reduction in spine density in VPA-treated mice via a prefrontal dopaminergic system-dependent mechanism. En ligne : http://dx.doi.org/10.1002/aur.1596 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=294

Motivational incentives and methylphenidate enhance electrophysiological correlates of error monitoring in children with attention deficit/hyperactivity disorder / Madeleine J. GROOM in Journal of Child Psychology and Psychiatry, 54-8 (August 2013)  

Permalink

Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial / Diane PURPER-OUAKIL in Journal of Child Psychology and Psychiatry, 63-2 (February 2022)  

Permalink

Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability / Emily SIMONOFF in Journal of Child Psychology and Psychiatry, 54-5 (May 2013)  

Permalink

A randomized controlled trial into the effects of neurofeedback, methylphenidate, and physical activity on EEG power spectra in children with ADHD / Tieme W.P. JANSSEN in Journal of Child Psychology and Psychiatry, 57-5 (May 2016)  

Permalink

Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate / Elizabeth B. LIDDLE in Journal of Child Psychology and Psychiatry, 52-7 (July 2011)  

Permalink